Most asthma treatments — inhalers, biologics, leukotriene modifiers — work by managing symptoms. They control the inflammatory cascade and open the airways, but they do not change the underlying immune response that triggers asthma in the first place. Allergen immunotherapy is different. It is the only treatment proven to induce lasting immunological tolerance to the allergens that drive asthma attacks, with benefits that can persist for years after treatment ends.
In South Florida's year-round high-allergen environment — house dust mites thriving in humid air, bahia and Bermuda grass pollinating all year, cockroach allergens in older buildings, Australian pine and Brazilian pepper causing intense seasonal reactions — allergen sensitization is a primary driver of asthma for a large proportion of patients in Plantation, Fort Lauderdale, and Broward County.
At Advanced Asthma Clinic, Dr. Frank Hull evaluates whether allergen immunotherapy is appropriate as part of a comprehensive asthma management plan. This page explains the science, the protocols, the outcomes, and who is and is not a good candidate.
What Is Allergen Immunotherapy?
Allergen immunotherapy is a medical treatment in which gradually increasing doses of specific allergen extracts are administered — either by injection (subcutaneous immunotherapy, SCIT) or under the tongue (sublingual immunotherapy, SLIT) — to desensitize the immune system and retrain it to tolerate allergen exposure without triggering asthma, allergic rhinitis, or anaphylaxis.
The concept dates to 1911, when Noon and Freeman first described "prophylactic inoculation against hay fever." More than a century of clinical research has refined the practice into evidence-based protocols with well-defined dosing schedules, safety standards, and outcome benchmarks. Immunotherapy is endorsed by GINA (Global Initiative for Asthma), the AAAAI (American Academy of Allergy, Asthma & Immunology), and EAACI (European Academy of Allergy and Clinical Immunology) as a disease-modifying treatment for allergic asthma when appropriate patient selection criteria are met.
Inhalers and most asthma medications are effective while you take them. Allergen immunotherapy produces lasting immunological changes — including regulatory T-cell induction and IgG4 blocking antibody generation — that can persist for years after the treatment course ends. This is the key distinction that makes immunotherapy an important option for patients with confirmed allergic sensitization driving their asthma.
How Allergy Shots Work: The Immunological Mechanism
Immunotherapy Mechanism — Step by Step
SCIT vs. SLIT: Comparing the Two Delivery Methods
| Feature | SCIT — Subcutaneous Injections | SLIT — Sublingual Drops/Tablets |
|---|---|---|
| Administration | Injections in clinic (deltoid area) | Drops or tablets under the tongue at home |
| Allergen coverage | Multiple allergens simultaneously (custom mix) | FDA-approved single-allergen tablets (grass, dust mite); multi-allergen drops off-label |
| Evidence for asthma | Strongest — decades of RCT data; GINA recommended | Strong for grass pollen and dust mite asthma; fewer multi-allergen RCTs |
| Systemic reaction risk | ~1 per 1 million injections (anaphylaxis); 30-min clinic observation required | Lower systemic risk; local oral reactions common; first dose given in clinic |
| Convenience | Weekly clinic visits (build-up), then monthly (maintenance) | Daily at home after first dose; no regular clinic visits for dosing |
| Build-up duration | 3–6 months (conventional); 6–12 weeks (cluster); 1–3 days (rush) | Variable; often 3–4 months before full maintenance |
| Maintenance duration | 3–5 years recommended | 3–5 years recommended |
| FDA-approved products | Custom allergen extracts (not individually FDA-approved as drugs) | Grastek, Oralair (grass); Odactra (dust mite); Ragwitek (ragweed) |
| Best suited for | Multi-allergen sensitization; severe allergic asthma; patients with confirmed SCIT eligibility | Single dominant allergen (grass, dust mite); needle-averse patients; some pediatric patients |
South Florida Allergens Treated with Immunotherapy
Broward County's subtropical climate creates one of the highest year-round allergen burdens in the United States. The following allergens most commonly drive allergic asthma in our patient population and are included in immunotherapy protocols:
House Dust Mite
Dermatophagoides pteronyssinus and farinae thrive year-round in South Florida's humidity. The dominant allergen in perennial asthma. Both SCIT and FDA-approved SLIT (Odactra) are effective. HDM is present in mattresses, carpets, and upholstered furniture.
Grass Pollens
Bahia grass and Bermuda grass pollinate nearly year-round in South Florida, with peaks in spring and fall. Bahia grass is among the most potent asthma triggers in Broward County. Both SCIT and FDA-approved SLIT tablets (Grastek, Oralair) treat grass sensitization.
Tree Pollens
Australian pine (Casuarina), Brazilian pepper (Schinus), oak, and melaleuca are significant South Florida sensitizers. Peak season December through March. Currently addressed only through SCIT (no FDA-approved SLIT products).
Cockroach Allergen
Blattella germanica (German cockroach) allergen is a major asthma trigger in multi-family housing and older buildings throughout Broward County. SCIT protocols including cockroach extract are available for sensitized patients.
Cat & Dog Dander
Fel d 1 (cat) and Can f 1 (dog) allergens are potent asthma triggers even in households without pets, as dander is carried on clothing. Pet ownership is near-universal; avoidance is rarely sufficient. SCIT effectively desensitizes pet-allergic asthma patients.
Mold Spores
Alternaria alternata and Cladosporium species surge during South Florida's rainy season (June–October). Alternaria sensitization correlates with severe asthma exacerbation risk. Mold SCIT protocols are more complex and require specialist experience.
Patient Eligibility for Allergen Immunotherapy
Good Candidates (SCIT/SLIT May Be Appropriate)
- Allergic asthma with confirmed IgE sensitization (skin test or specific IgE positive)
- Asthma symptoms triggered by identifiable allergen(s)
- Mild-to-moderate asthma with FEV1 ≥70% predicted on optimal therapy
- Inadequate control on standard pharmacotherapy
- Desire to reduce long-term medication burden
- Co-existing allergic rhinitis and/or atopic dermatitis
- Children: to prevent sensitization spreading and asthma persistence
- Patients preferring disease-modification over lifelong symptom management
Relative or Absolute Contraindications
- Severe uncontrolled asthma (FEV1 <70% on optimal therapy) — elevated anaphylaxis risk
- Active beta-blocker use (impairs epinephrine rescue if reaction occurs)
- Ischemic heart disease or severe cardiovascular disease
- Active malignancy or immune-compromising treatment
- Non-allergic (intrinsic) asthma with no IgE sensitization
- Pregnancy (do not initiate; may continue established maintenance)
- Severe or unstable asthma exacerbation — defer until controlled
- Age under 5 years (evidence limited; specialist assessment required)
All SCIT injections must be given in a clinical setting equipped with epinephrine and resuscitation equipment. Patients remain under observation for 20–30 minutes after each injection. The risk of systemic allergic reaction is approximately 1 per 1 million injections, but when reactions occur, clinic observation allows immediate treatment. Never receive allergy shots without this safety protocol in place.
The Allergy Shot Protocol: What to Expect
-
Comprehensive Allergy Testing
Skin prick testing (SPT) or intradermal testing identifies the specific allergens driving your asthma. Alternatively, a specific IgE blood panel (ImmunoCAP) quantifies sensitization. Testing must precede immunotherapy design — blind polypharmacy without knowing your allergen profile is ineffective and potentially unsafe.
-
Custom Allergen Extract Formulation
Based on testing results, a custom allergen extract vial is prepared containing your specific sensitizing allergens. The starting concentration is calculated based on your degree of skin test reactivity — more sensitive patients begin at very low doses to avoid reactions.
-
Build-Up Phase (3–6 Months)
Weekly injections with progressively increasing allergen dose. Conventional build-up takes 3–6 months. Cluster immunotherapy (2–3 injections per visit, 1–2 visits per week) can shorten build-up to 6–10 weeks. Rush immunotherapy (hospital-based rapid escalation over 1–3 days) achieves the fastest build-up but requires closest monitoring.
-
Maintenance Phase (3–5 Years)
Once the target maintenance dose is reached, injections transition to monthly (sometimes every 6–8 weeks in some protocols). The maintenance dose is the effective therapeutic dose that produces immune tolerance. Most patients notice meaningful asthma improvement 6–18 months into maintenance.
-
Monitoring & Dose Adjustment
Spirometry and asthma control scores are assessed at regular intervals. If a large allergen exposure occurs (high pollen day, pet encounter) before an injection visit, dose may be temporarily reduced. Significant asthma exacerbations require dose deferral until symptoms are controlled.
-
Discontinuation Decision
After 3–5 years of maintenance, clinical and objective reassessment determines whether immunotherapy is stopped. Patients who respond well and have sustained improvement can discontinue. Those with continued exposure to high allergen loads or incomplete response may benefit from continued maintenance beyond 5 years. Consult your physician for individualized guidance.
Immunotherapy Timeline Phases at a Glance
Weekly injections. Starting dose: dilute (e.g., 1:100,000 or 1:10,000 of maintenance concentrate). Dose escalated by ~25–30% each visit toward target maintenance concentration. Temporary local reactions (redness, swelling at injection site) are common and expected. Systemic reactions are monitored with 30-minute post-injection observation.
Monthly injections at target dose. Asthma symptoms typically begin improving 6–12 months into maintenance. Peak benefit at 18–24 months. IgG4 blocking antibodies rise; IgE-driven mast cell reactivity decreases. Asthma medication requirements often reduce. Ongoing spirometry monitoring continues.
After completing the full course, many patients retain meaningful tolerance for 3–7 years, with some maintaining benefit indefinitely. Children treated early may show prevention of new sensitizations and reduced asthma persistence into adulthood. This durable benefit is unique to immunotherapy — no other asthma treatment produces comparable post-treatment persistence.
How Immunotherapy Complements Other Asthma Treatments
Allergen immunotherapy is not a replacement for asthma controller medications — it works alongside them. The typical clinical approach at Advanced Asthma Clinic for allergic asthma patients:
- ICS or ICS+LABA continues during the full immunotherapy course as the primary pharmacological controller
- Allergen avoidance measures are reinforced in parallel: dust mite mattress encasements, HEPA filtration, cockroach control
- Biologic therapy may be appropriate alongside or instead of immunotherapy for severe eosinophilic asthma: dupilumab, mepolizumab, and tezepelumab do not interfere with immunotherapy and can be co-administered in carefully selected patients — see our page on biologic therapy for severe asthma
- Allergic rhinitis treatment is managed simultaneously, as rhinitis and asthma share a unified airway — nasal corticosteroids, antihistamines, and immunotherapy all reduce upper airway inflammation that amplifies asthma
- Asthma action plan is updated to reflect target medication step-down goals as immunotherapy takes effect
Because allergic rhinitis and allergic asthma share the same Type 2 inflammatory pathway (the "unified airway"), allergen immunotherapy treats both simultaneously. Patients frequently report that their nasal symptoms improve significantly — often before their asthma improves — as a first sign that the immune response is shifting. This dual benefit is particularly valuable for South Florida patients with year-round pollen and mold exposure driving both upper and lower airway disease.
What the Evidence Says: Clinical Outcomes
Allergen immunotherapy for asthma has been studied in hundreds of randomized controlled trials. Key outcome data:
- Asthma symptom scores: Meta-analyses consistently show 20–40% reduction vs. pharmacotherapy alone
- Rescue inhaler use: Reduced by approximately 30–40% in responders
- Exacerbation rate: Significantly reduced; some studies show 50%+ reduction in hospitalization risk in children
- Medication step-down: Many patients achieve reduction in ICS dose or step down from ICS+LABA to ICS alone after 2–3 years of immunotherapy
- Lung function: FEV1 improvements of 5–15% documented in controlled trials vs. placebo
- New sensitization prevention (children): Children treated with SCIT show ~50% reduction in the development of new allergen sensitizations over 3–7 year follow-up
- Asthma prevention (rhinitis-only patients): Among patients with allergic rhinitis but no asthma, immunotherapy reduces the risk of developing asthma by approximately 40–60% over 3 years
- Sustained post-treatment benefit: Studies show meaningful symptom control persisting 3–7 years after completing a full 3–5 year course
It is important to note that immunotherapy response varies considerably between patients. The strongest predictors of good response include: fewer allergen sensitivities (ideally one dominant allergen), high skin-test reactivity, younger age at treatment initiation, good asthma control before starting, and full completion of the recommended course. Consult your physician to assess your individual likelihood of response.
Allergen Immunotherapy for Asthma in Broward County
South Florida's unique allergen calendar means that asthma patients in Plantation, Fort Lauderdale, Davie, Pembroke Pines, and across Broward County face allergen exposure in virtually every month of the year. This creates two challenges: it increases the cumulative trigger burden on airways, and it makes simple allergen avoidance almost impossible.
For these patients, allergen immunotherapy represents a particularly compelling strategy. Rather than adding another inhaler to manage symptoms driven by unavoidable allergen exposure, immunotherapy progressively reduces the immune hypersensitivity that makes those exposures dangerous. Over the 3–5 year treatment course, many Broward County patients with allergic asthma find they can tolerate pollen seasons and outdoor activities that previously forced them indoors.
Dr. Frank Hull's evaluation includes a detailed allergen history mapped to South Florida's specific calendar — which pollens, which molds, which months — and integrates this with skin testing and lung function data to determine whether immunotherapy is the right next step in your asthma management.
Frequently Asked Questions — Allergy Shots & Immunotherapy for Asthma
Allergy shots do not cure asthma, but they can produce long-lasting disease modification that continues after the shot series ends. Meta-analyses show allergen immunotherapy reduces asthma symptom scores by 20–40%, decreases rescue inhaler use, lowers exacerbation frequency, and can reduce or eliminate the need for controller medications in well-selected patients.
Some patients achieve sustained remission-like states lasting years after completing the full 3–5 year course. This is distinct from other asthma medications, which provide no ongoing benefit after discontinuation. Consult your physician to assess whether immunotherapy is appropriate for your specific asthma profile.
Most patients notice meaningful improvement in asthma symptoms between 6 and 12 months into the build-up phase, as doses increase toward the maintenance level. Maximum benefit typically occurs after 12–18 months of maintenance dosing. The complete recommended course is 3–5 years of maintenance injections.
Stopping early significantly reduces the duration of lasting benefit. SLIT tablets may show earlier symptom response — sometimes within 4 months — for grass pollen-triggered asthma, though the full course is still recommended for sustained effect.
Allergy shots carry a small but real risk of systemic allergic reactions, including anaphylaxis (approximately 1 per 1 million injections). For this reason, GINA and AAAAI guidelines recommend against initiating SCIT in patients with severe uncontrolled asthma (FEV1 below 70% predicted on optimal therapy) due to the elevated risk of severe systemic reactions.
Asthma must be well-controlled before starting immunotherapy. All injections are given in a clinical setting with a 20–30 minute observation period. Sublingual immunotherapy (SLIT) carries a lower systemic reaction risk and may be appropriate for some patients with moderate disease. Consult your physician to determine eligibility.
In South Florida and Broward County, the most clinically significant allergens for asthma immunotherapy include: house dust mite (Dermatophagoides pteronyssinus and farinae), grass pollens (Bermuda, bahia), tree pollens (oak, Australian pine, Brazilian pepper), cockroach allergens, and cat/dog dander. Mold sensitivity (Alternaria, Cladosporium) can also be addressed, though mold SCIT protocols require specialist experience.
Skin prick testing or specific IgE blood testing identifies which allergens are driving each patient's asthma before immunotherapy is designed. Treating allergens that are not clinically relevant wastes time and resources.
SCIT (subcutaneous immunotherapy) involves injections given in a clinic, starting weekly and transitioning to monthly. It can treat multiple allergens simultaneously and has the strongest evidence base for asthma. SLIT (sublingual immunotherapy) involves allergen drops or dissolving tablets placed under the tongue, taken daily at home. FDA-approved SLIT tablets exist for grass pollen (Grastek, Oralair) and house dust mite (Odactra).
SLIT carries lower systemic reaction risk and is more convenient for patients who cannot visit the clinic frequently, but is currently limited to single allergen classes in its approved form. Both modalities produce disease-modifying benefit in allergic asthma. Your physician can advise which is more appropriate based on your allergen sensitization pattern and asthma severity.
Most major health insurance plans, including Medicare and many Medicaid plans, cover allergen immunotherapy when medically indicated for allergic asthma. Coverage typically requires documentation of allergic sensitization (positive skin test or IgE), allergic asthma diagnosis, and inadequacy of standard pharmacotherapy alone.
Out-of-pocket costs vary by plan, deductible, and co-pay structure. Our office can assist with prior authorization and insurance verification. Call 954-522-7226 to discuss coverage before starting treatment.
Yes. Allergen immunotherapy is safe and effective in children as young as 5 years old and is particularly valuable in pediatric allergic asthma because it can modify the underlying allergic trajectory — potentially preventing new sensitizations and reducing the risk of asthma persistence into adulthood. GINA guidelines support allergen immunotherapy for children with mild-to-moderate allergic asthma.
SLIT tablets may be preferred in younger children who are needle-averse. Skin testing in children requires careful allergen selection and dose adjustment. Consult your physician for an individualized pediatric assessment.
Ready to Treat the Root Cause of Your Allergic Asthma?
Dr. Frank Hull at Advanced Asthma Clinic evaluates allergen immunotherapy eligibility as part of comprehensive asthma management. Skin testing, spirometry, and full asthma assessment in Plantation, FL — serving Broward County and South Florida.
Call 954-522-7226 Request Appointment OnlineRelated Resources
- Allergic Asthma Overview
- Asthma & Allergic Rhinitis (Unified Airway)
- Asthma & Pollen
- Dust Mite Allergy & Asthma
- Biologic Therapy for Severe Asthma
- Asthma & Pet Allergens
- Asthma & Mold
- Atopic March — From Eczema to Asthma